XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2023 and 2022 (in thousands, except share and per share amounts):

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(57,699

)

 

$

(62,736

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

143,511,142

 

 

 

141,697,252

 

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(0.40

)

 

$

(0.44

)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2023 and 2022, as they had an anti-dilutive effect:

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Stock options outstanding

 

 

13,800,485

 

 

 

13,255,459

 

Nonvested restricted stock units outstanding

 

 

7,386,862

 

 

 

2,587,492

 

Maximum nonvested market-based restricted stock units outstanding eligible to be earned

 

 

904,006

 

 

 

153,762

 

Total

 

 

22,091,353

 

 

 

15,996,713